Double-blind clinical trial of acyclovir and adenine arabinoside in herpetic corneal ulceration.
The results of a double-blind clinical trials of acyclovir and adenosine arabinoside (ara-A) in 93 patients with herpetic keratitis demonstrated a significantly faster healing rate for acyclovir (p less than 0.01). Ulcers in 45 (94 percent) of acyclovir-treated patients and 37 (82 percent) of ara-A-treated patients healed within 14 days. No serious side effects were observed.
D000212:Acyclovir; D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007635:Keratitis, Dendritic / Q000188:drug therapy*; D008297:Male; D014456:Ulcer / Q000188:drug therapy; D014740:Vidarabine / Q000627:therapeutic use*
D000998:Antiviral Agents; D006147:Guanine; D014740:Vidarabine; D000212:Acyclovir